XGN Projected Dividend Yield
Exagen Inc ( NASDAQ : XGN )Exagen engages in the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling differential diagnosis and improving therapeutic intervention. Co. commercializes a portfolio of testing products under its AVISE® brand, several of which incorporate Cell-Bound Complement Activation Products (CB-CAPs) technology. CB-CAPs assess the activation of the complement system, a biological pathway that is implicated across various autoimmune and autoimmune-related diseases. Co.'s testing product, AVISE® CTD, enables differential diagnosis for patients presenting with symptoms indicative of connective tissue diseases and other diseases with overlapping symptoms. 20 YEAR PERFORMANCE RESULTS |
XGN Dividend History Detail XGN Dividend News XGN Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |